JP2011512374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512374A5 JP2011512374A5 JP2010547116A JP2010547116A JP2011512374A5 JP 2011512374 A5 JP2011512374 A5 JP 2011512374A5 JP 2010547116 A JP2010547116 A JP 2010547116A JP 2010547116 A JP2010547116 A JP 2010547116A JP 2011512374 A5 JP2011512374 A5 JP 2011512374A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- disorder
- withdrawal symptoms
- anxiety
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001598 anti-natriuretic effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 229940005483 opioid analgesics Drugs 0.000 claims description 2
- 229940052318 opioid anesthetics Drugs 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003957 neurotransmitter release Effects 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08003238 | 2008-02-22 | ||
| EP08003238.6 | 2008-02-22 | ||
| PCT/EP2009/001232 WO2009103552A1 (en) | 2008-02-22 | 2009-02-20 | Substituted indole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512374A JP2011512374A (ja) | 2011-04-21 |
| JP2011512374A5 true JP2011512374A5 (enExample) | 2014-09-18 |
| JP5635914B2 JP5635914B2 (ja) | 2014-12-03 |
Family
ID=39449548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547116A Expired - Fee Related JP5635914B2 (ja) | 2008-02-22 | 2009-02-20 | 置換インドール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090215828A1 (enExample) |
| EP (1) | EP2254883B1 (enExample) |
| JP (1) | JP5635914B2 (enExample) |
| CN (1) | CN102015683B (enExample) |
| AR (1) | AR070398A1 (enExample) |
| AU (1) | AU2009216920B2 (enExample) |
| CA (1) | CA2716270C (enExample) |
| CL (1) | CL2009000404A1 (enExample) |
| IL (1) | IL207684A (enExample) |
| MX (1) | MX2010009045A (enExample) |
| PE (1) | PE20091490A1 (enExample) |
| RU (1) | RU2500677C2 (enExample) |
| WO (1) | WO2009103552A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| TW201020247A (en) * | 2008-11-06 | 2010-06-01 | Gruenenthal Gmbh | Substituierte disulfonamide |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| KR20140095073A (ko) | 2011-11-04 | 2014-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 치료 방법 |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| MX2019005679A (es) | 2016-11-18 | 2019-08-14 | Merck Sharp & Dohme | Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| AU2018231120B2 (en) * | 2017-03-10 | 2022-06-23 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| US20240408064A1 (en) * | 2021-10-15 | 2024-12-12 | Genetolead Inc. | Ras inhibitors, compositions and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1586817A (en) * | 1977-12-01 | 1981-03-25 | Wyeth John & Brother Ltd | Indole derivatives |
| JP3314938B2 (ja) * | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| DE60026581T2 (de) * | 1999-12-20 | 2006-12-28 | Eli Lilly And Co., Indianapolis | Indolderivate zur behandlung von depression und angstzuständen |
| DE10153346A1 (de) * | 2001-10-29 | 2004-04-22 | Grünenthal GmbH | Substituierte Indole |
| DE10252650A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-Harnstoff-Derivate |
| DE10252666A1 (de) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| WO2005047253A1 (en) * | 2003-11-12 | 2005-05-26 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2641817A1 (en) * | 2006-02-01 | 2007-08-09 | Solvay Pharmaceuticals Gmbh | Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparation |
| US20070219214A1 (en) * | 2006-02-01 | 2007-09-20 | Solvay Pharmaceuticals Gmbh | Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation |
| CA2682483A1 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
-
2009
- 2009-02-16 AR ARP090100544A patent/AR070398A1/es not_active Application Discontinuation
- 2009-02-19 US US12/388,977 patent/US20090215828A1/en not_active Abandoned
- 2009-02-20 WO PCT/EP2009/001232 patent/WO2009103552A1/en not_active Ceased
- 2009-02-20 MX MX2010009045A patent/MX2010009045A/es active IP Right Grant
- 2009-02-20 RU RU2010138838/04A patent/RU2500677C2/ru not_active IP Right Cessation
- 2009-02-20 CN CN200980115064.3A patent/CN102015683B/zh not_active Expired - Fee Related
- 2009-02-20 JP JP2010547116A patent/JP5635914B2/ja not_active Expired - Fee Related
- 2009-02-20 AU AU2009216920A patent/AU2009216920B2/en not_active Ceased
- 2009-02-20 CL CL2009000404A patent/CL2009000404A1/es unknown
- 2009-02-20 EP EP09713555.2A patent/EP2254883B1/en not_active Not-in-force
- 2009-02-20 CA CA2716270A patent/CA2716270C/en not_active Expired - Fee Related
- 2009-02-20 PE PE2009000247A patent/PE20091490A1/es not_active Application Discontinuation
-
2010
- 2010-08-19 IL IL207684A patent/IL207684A/en not_active IP Right Cessation
-
2012
- 2012-12-11 US US13/710,604 patent/US9206156B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512374A5 (enExample) | ||
| JP2009543825A5 (enExample) | ||
| JP2011517670A5 (enExample) | ||
| JP2011515430A5 (enExample) | ||
| JP2012526061A5 (enExample) | ||
| JP2009538866A5 (enExample) | ||
| Julio-Pieper et al. | Regulation of the brain–gut axis by group III metabotropic glutamate receptors | |
| JP2011515429A5 (enExample) | ||
| RS52526B2 (sr) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| JP2008524262A5 (enExample) | ||
| WO2005075436A3 (en) | Novel inhibitors of glutaminyl cyclase | |
| TW201144302A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | |
| WO2011041526A3 (en) | Non-invasive method to treat urological and gastrointestinal disorders | |
| JP2010536849A5 (enExample) | ||
| JP2011517669A5 (enExample) | ||
| JP2009538867A5 (enExample) | ||
| JP2010523492A5 (enExample) | ||
| WO2009138762A3 (en) | Therapeutic use of peptides | |
| Maguire-Zeiss | α-Synuclein: A therapeutic target for Parkinson’s disease? | |
| UY27735A1 (es) | Hidrato de un antagonista de receptores muscarínicos. | |
| JP2013538206A5 (enExample) | ||
| WO2009109493A3 (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists | |
| JP2007509960A5 (enExample) | ||
| TW200613255A (en) | Therapeutic diphenyl ether ligands | |
| JP2009502914A5 (enExample) |